Renin-angiotensin System Inhibitors in the COVID-19 Pandemic: Consequences of Antihypertensive Drugs

Simple item page
dc.contributor.authorRuilope Urioste, Luis Miguel
dc.contributor.authorTamargo, Juan
dc.contributor.authorRuiz Hurtado, Gema
dc.date.accessioned2020-07-07T14:34:04Z
dc.date.available2020-07-07T14:34:04Z
dc.date.issued2020
dc.description.filiationUEMspa
dc.description.impact29.983 JCR (2020) Q1, 2/142 Cardiac & Cardiovascular Systemsspa
dc.description.impact4.336 SJR (2020) Q1, 9/349 Cardiology and Cardiovascular Medicinespa
dc.description.impactNo data IDR 2020spa
dc.description.sponsorshipSin financiaciónspa
dc.identifier.citationRuilope Urioste, L. M., Tamargo, J., & Ruiz-Hurtado, G. (2020). Renin–angiotensin system inhibitors in the COVID-19 pandemic: Consequences of antihypertensive drugs. European Heart Journal, 41(22), 2067–2069. https://doi.org/10.1093/eurheartj/ehaa487spa
dc.identifier.doi10.1093/eurheartj/ehaa487
dc.identifier.issn0195-668X
dc.identifier.issn1522-9645
dc.identifier.urihttp://hdl.handle.net/11268/9020
dc.language.isoengspa
dc.peerreviewedSispa
dc.relation.publisherversionhttps://doi.org/10.1093/eurheartj/ehaa487spa
dc.rights.accessRightsopen accessspa
dc.subject.uemHipertensiónspa
dc.subject.uemMedicamentos cardiovascularesspa
dc.subject.uemCOVID-19spa
dc.subject.unescoEnfermedad cardiovascularspa
dc.subject.unescoMedicamentospa
dc.subject.unescoVirologíaspa
dc.titleRenin-angiotensin System Inhibitors in the COVID-19 Pandemic: Consequences of Antihypertensive Drugsspa
dc.typejournal articlespa
dspace.entity.typePublication

Files

Collections

Otras Áreas de Investigación de Salud